Ser1270
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser1270  -  ATM (human)

Site Information
SHFDEVksIANQIQE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1881548600

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
prostate cancer ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
CK1A (human) ( 1 )
Kinases, in vitro:
CK1A (human) ( 1 )
Treatments:
BTX-A51 ( 1 ) , D4476 ( 1 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on ATM:
protein degradation ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
apoptosis, inhibited ( 1 ) , carcinogenesis, induced ( 1 ) , cell growth, induced ( 1 ) , DNA repair, inhibited ( 1 ) , transcription, altered ( 1 )

References 

1

Liu J, et al. (2023) A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer. Cell Rep Med 4, 101015
37075701   Curated Info